Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells

Immune checkpoint inhibitors (CI) have demonstrated clinical activity in Hodgkin Lymphoma (HL) patients relapsing after autologous stem cell transplantation (ASCT), although only 20% complete response (CR) rate was observed. The efficacy of CI is strictly related to the host immune competence, which...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fabio Guolo, Paola Minetto, Silvia Pesce, Filippo Ballerini, Marino Clavio, Michele Cea, Michela Frello, Matteo Garibotto, Marco Greppi, Matteo Bozzo, Maurizio Miglino, Monica Passannante, Riccardo Marcolin, Elisabetta Tedone, Nicoletta Colombo, Rosa Mangerini, Alessandra Bo, Maria Rosaria Ruzzenenti, Paolo Carlier, Alberto Serio, Silvia Luchetti, Alida Dominietto, Riccardo Varaldo, Simona Candiani, Vanessa Agostini, Jean Louis Ravetti, Genny Del Zotto, Emanuela Marcenaro, Roberto Massimo Lemoli
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Hodgkin lymphoma
nivolumab
natural killer cells
programmed cell death receptor 1
NK cell maturation
immune check point
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/8a2f7160a3604c7ab74567cee42b953c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares